Antihypertensive effect of the SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes
DOI:
https://doi.org/10.52692/1857-0011.2024.1-78.21Keywords:
dapagliflozin, hypertension, type 2 diabetesAbstract
Chronic pathologies that disable over time, such as hypertension and type 2 diabetes, remain among the top targets of international studies and approaches. That’s why the scientists, as well as the staff of the practical bases, have nothing left but to impose the development and implementation of the new preparations, which would be able to meet their needs. An important step would be to synthesize drug molecules with positive effects in concomitant pathologies, which most often meet in pairs or complement each other through the adverse effects they produce on the human body. Such a preparation, which is currently approached through the prism of the multitude of positive effects, is in full company of implementation in the treatment of several chronic pathologies such as type 2 diabetes mellitus, chronic heart failure, chronic renal failure and makes part of the group of SGLT 2 inhibitors is the dapagliflozin.The antihypertensive effect of dapagliflozin is relevant and requires a well-documented analysis in this direction
References
Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):110–116.i: 10.2174/1570161117666190405165151. [PubMed] [CrossRef] [Google Scholar]
Lan C, Qianyu F, Longhua Z, Yuqin F, Fenfen L, Yuanyuan F, et al. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci Rep. 2022;12(1):3525. doi: 10.1038/s41598-022-07395-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Roumie CL, Hung AM, Russell GB, Basile J, Kreider KE, Nord J, et al. Blood pressure control and the association with diabetes mellitus incidence: results from SPRINT randomized trial. Hypertension. 2020;75(2):331–338. doi: 10.1161/HYPERTENSIONAHA.118.12572. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57(5):891–897. doi: 10.1161/HYPERTENSIONAHA.110.162446. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713–720
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–713.
Standards of medical care in diabetes–2014. Diabetes Care 2014; 37(Suppl. 1): S14–S80.
Paneni F. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. Diab Vasc Dis Res 2014; 11: 5–10
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657.
Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43
Dornfeld LP, Maxwell MH, Waks AU, et al. Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes 1985; 9: 381–389
Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001; 9: 188–195.
C David Sjöström1, Peter Johansson1, Agata Ptaszynska2, James List2,3 and Eva Johnsson1, Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes, Diabetes & Vascular Disease Research 2015, Vol. 12(5) 352–358
Qin Zhang1 , Siyuan Zhou1 and Lijun Liu2*, Efcacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis, Zhang et al. Diabetology & Metabolic Syndrome (2023) 15:118
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
